



## **GNI Receives F351 Patent Allowance in Canada**

**Tokyo, August 26, 2010** – GNI Ltd, a leading biopharmaceutical company in Japan and China, is pleased to announce that the Canada Intellectual Property Office has sent Notice of Allowance to Shanghai Genomics, its wholly owned subsidiary in China, on a patent application covering the composition and usage of F351 for fibrosis therapy. In addition to China (2007) and Australia (2009), this is the third country giving GNI intellectual property protection on F351. Patent applications in Japan, US and Europe are still under review by individual country.

F351 is the Company's lead product against liver fibrosis. A human Phase I trial has just completed with satisfactory safety and PK profiles. Preparation for Phase II human trial is in progress. On July 30, 2010, GNI and EPS also announced a plan to co-develop F351 for liver fibrosis patients in China.

"Patent allowance outside China will enable us to develop this drug for markets in other countries. It will also give us possibilities to work with more corporate partners in the future. Such kind of co-development partnership will not only improve our finance balance sheet, but also help GNI to become a credible international biotech player," said Luo, CEO of GNI and Shanghai Genomics.

### **About GNI**

Founded in 2001, GNI, Ltd. is a clinical-stage international drug development company with its headquarters in Tokyo, Japan, and research operations in Shanghai, China. In June 2005, GNI acquired Shanghai Genomics, which was also founded in 2001, and currently operates an integrated drug discovery and development platform in Shanghai. The combined strengths of GNI and Shanghai Genomics have resulted in research collaborations with major international pharmaceutical companies. For further information, please visit [www.qnipharma.com](http://www.qnipharma.com) and [www.shanghaigenomics.com](http://www.shanghaigenomics.com).

### **For further inquiries**

Shinobu Tanaka	Tel: +81 (03) -5326-3097 Email: <a href="mailto:ir@gene-networks.com">ir@gene-networks.com</a>
Ying Luo	Tel: +86 1381-769-8961 Email: <a href="mailto:bd@shanghaigenomics.com">bd@shanghaigenomics.com</a>

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to," "will," "intend to," "strive to" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. There is no guarantee that SFDA of China may approve the Company's NDA application. GNI does not undertake any obligation to update forward-looking statements.